



## Clinical trial results:

### A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

#### Summary

EudraCT number	2016-002025-11
Trial protocol	GB DE SE BE CZ DK PT FI ES NL AT EE PL IT
Global end of trial date	28 February 2023

#### Results information

Result version number	v2 (current)
This version publication date	21 September 2023
First version publication date	08 July 2020
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	ALXN1210-PNH-301
-----------------------	------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02946463
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Alexion Pharmaceuticals Inc.
Sponsor organisation address	121 Seaport Boulevard, Boston, MA, United States, 02210
Public contact	European Clinical Trial Information, Alexion Pharmaceuticals Inc., +33 147100606, clinicaltrials.eu@alexion.com
Scientific contact	European Clinical Trial Information, Alexion Pharmaceuticals Inc., +33 147100606, clinicaltrials.eu@alexion.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 February 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 January 2018
Global end of trial reached?	Yes
Global end of trial date	28 February 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the countries in which the study was conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 December 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 5
Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	Sweden: 1
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	Austria: 6
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Czechia: 2
Country: Number of subjects enrolled	Estonia: 2
Country: Number of subjects enrolled	France: 28
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Argentina: 4
Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	Brazil: 16
Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	Italy: 8
Country: Number of subjects enrolled	Japan: 34
Country: Number of subjects enrolled	Malaysia: 30

Country: Number of subjects enrolled	Mexico: 2
Country: Number of subjects enrolled	Russian Federation: 46
Country: Number of subjects enrolled	Singapore: 2
Country: Number of subjects enrolled	Korea, Republic of: 40
Country: Number of subjects enrolled	Taiwan: 9
Country: Number of subjects enrolled	Thailand: 8
Country: Number of subjects enrolled	Turkey: 1
Country: Number of subjects enrolled	United States: 5
Worldwide total number of subjects	272
EEA total number of subjects	65

Notes:

---

### **Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	2
Adults (18-64 years)	234
From 65 to 84 years	35
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

24 adult and 2 paediatric participants rolled over from other Alexion ongoing studies of ravulizumab intravenous in participants with PNH into the extension period of this study and received weight-based doses of ravulizumab for up to 5 years.

### Pre-assignment

Screening details:

Due to database limitations, data for the 26 rolled over participants are reported under "Ravulizumab: Extension Period" and data are reported under separate columns in the Adverse Event module.

### Period 1

Period 1 title	Primary Evaluation
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ravulizumab: Primary Evaluation

Arm description:

Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.

Arm type	Experimental
Investigational medicinal product name	Ravulizumab
Investigational medicinal product code	
Other name	Ultomiris, ALXN1210
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received weight-based loading doses of ravulizumab ranging from 2400 to 3000 mg on Day 1. Thereafter, weight-based maintenance doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.

<b>Arm title</b>	Eculizumab: Primary Evaluation
------------------	--------------------------------

Arm description:

Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.

Arm type	Experimental
Investigational medicinal product name	Eculizumab
Investigational medicinal product code	
Other name	Soliris
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 600-mg induction doses of eculizumab on Days 1, 8, 15, and 22, followed by 900-mg maintenance doses of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.

<b>Number of subjects in period 1</b> <sup>[1]</sup>	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation
Started	125	121
Received at Least 1 Dose of Study Drug	125	121
Completed	125	119
Not completed	0	2
Physician decision	-	1
Consent withdrawn by subject	-	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 24 adult and 2 paediatric participants rolled over from other Alexion ongoing studies of ravulizumab intravenous in participants with PNH into the extension period of this study. The worldwide number enrolled includes the 26 participants that rolled into the extension period.

## Period 2

Period 2 title	Extension Period
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ravulizumab: Extension Period

Arm description:

After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 5 years.

Arm type	Experimental
Investigational medicinal product name	Ravulizumab
Investigational medicinal product code	
Other name	Ultomiris, ALXN1210
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Weight-based maintenance doses of ravulizumab ranging from 3000 to 3600 mg were administered every 8 weeks for up to 5 years.

<b>Arm title</b>	Eculizumab/Ravulizumab: Extension Period
------------------	--

Arm description:

After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 5 years.

Arm type	Experimental
Investigational medicinal product name	Ravulizumab
Investigational medicinal product code	
Other name	Ultomiris, ALXN1210
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received weight-based loading doses of ravulizumab ranging from 2400 to 3000 mg on Day 1. Thereafter, weight-based maintenance doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 5 years.

<b>Number of subjects in period 2<sup>[2]</sup></b>	Ravulizumab: Extension Period	Eculizumab/Ravulizumab: Extension Period
Started	124	119
Received at Least 1 Dose of Study Drug	150	119
Completed	132	102
Not completed	18	17
Physician decision	1	4
Consent withdrawn by subject	4	3
Adverse event, non-fatal	1	2
Death during the study	4	4
Pregnancy	3	1
Unspecified	4	3
Lost to follow-up	1	-
Joined	26	0
Rolled over from other Alexion studies	26	-

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 1 patient in the Ravulizumab group discontinued treatment but completed Week 26. The participant did not continue to the Extension Period but did not discontinue the study.

## Baseline characteristics

### Reporting groups

Reporting group title	Ravulizumab: Primary Evaluation
-----------------------	---------------------------------

Reporting group description:

Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.

Reporting group title	Eculizumab: Primary Evaluation
-----------------------	--------------------------------

Reporting group description:

Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.

Reporting group values	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation	Total
Number of subjects	125	121	246
Age categorical			
Measure Description: Age at first infusion of study drug			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	110	102	212
From 65-84 years	15	18	33
85 years and over	0	1	1
Age continuous			
Measure Description: Age at first infusion of study drug			
Units: years			
arithmetic mean	44.8	46.2	
standard deviation	± 15.16	± 16.24	-
Gender categorical			
Units: Subjects			
Female	60	52	112
Male	65	69	134
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	5	13	18
Not Hispanic or Latino	116	102	218
Unknown or Not Reported	4	6	10
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	1	1	2
Asian	72	57	129
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	2	4	6

White	43	51	94
More than one race	0	0	0
Unknown or Not Reported	7	8	15

## End points

### End points reporting groups

Reporting group title	Ravulizumab: Primary Evaluation
Reporting group description: Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.	
Reporting group title	Eculizumab: Primary Evaluation
Reporting group description: Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.	
Reporting group title	Ravulizumab: Extension Period
Reporting group description: After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 5 years.	
Reporting group title	Eculizumab/Ravulizumab: Extension Period
Reporting group description: After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 5 years.	

### Primary: Proportion Of Participants With Normalization Of LDH Levels

End point title	Proportion Of Participants With Normalization Of LDH Levels
End point description: Lactate dehydrogenase is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria (PNH). A decrease in LDH from above the upper limit of normal (ULN) to below the ULN indicates reduction (improvement) in hemolysis. Normalization of LDH levels (LDH-N) was LDH levels less than or equal to 1 x ULN, from Day 29 through Day 183. The ULN for LDH was 246 units/liter.	
End point type	Primary
End point timeframe: Day 29 through Day 183	

End point values	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	125	121		
Units: Proportion of Participants				
number (confidence interval 95%)	0.536 (0.459 to 0.612)	0.494 (0.417 to 0.570)		

### Statistical analyses

Statistical analysis title	Analysis of Normalization Of LDH
Statistical analysis description: A minimum of 142 participants were estimated to provide 80% power to demonstrate noninferiority of	

ravulizumab to eculizumab.

Comparison groups	Ravulizumab: Primary Evaluation v Eculizumab: Primary Evaluation
Number of subjects included in analysis	246
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[1]</sup>
Parameter estimate	Odds ratio (OR)
Point estimate	1.187
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.796
upper limit	1.769

Notes:

[1] - LDH-N was analyzed using a generalized estimating equation approach. The model included the following terms: treatment group, history of transfusion (as a categorical variable based on the stratification factor levels), and baseline LDH level (as a continuous variable). Noninferiority margin was based on the lower bound of the 95% confidence interval (CI) for the OR of ravulizumab versus eculizumab for LDH normalization being greater than an OR of 0.39.

### Primary: Percentage Of Participants Who Achieved Transfusion Avoidance

End point title	Percentage Of Participants Who Achieved Transfusion Avoidance
End point description:	The co-primary end point of transfusion avoidance (TA) was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines through Day 183.
End point type	Primary
End point timeframe:	Baseline through Day 183

End point values	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	125	121		
Units: Percentage of Participants				
number (confidence interval 95%)	73.6 (65.87 to 81.33)	66.1 (57.68 to 74.55)		

### Statistical analyses

Statistical analysis title	Analysis of TA
Statistical analysis description:	A minimum of 193 participants were estimated to provide 80% power to demonstrate noninferiority of ravulizumab to eculizumab. The difference of percentages were calculated using stratified Newcombe CI method. Stratification factors were: observed stratification groups of packed red blood cells (pRBC)/whole blood units transfused in the 1 year prior to first dose of study drug and screening LDH
Comparison groups	Ravulizumab: Primary Evaluation v Eculizumab: Primary Evaluation

Number of subjects included in analysis	246
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[2]</sup>
Parameter estimate	Treatment difference
Point estimate	6.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.66
upper limit	18.14

Notes:

[2] - Noninferiority margin was based on the lower bound of the 95% CI. Noninferiority margin was -20%.

### Secondary: Percentage Of Participants With Breakthrough Hemolysis

End point title	Percentage Of Participants With Breakthrough Hemolysis
-----------------	--

End point description:

Breakthrough hemolysis (BTH) was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath [dyspnea], anemia [hemoglobin < 10 gram/deciliter (g/dL)], major adverse vascular event [including thrombosis], dysphagia, or erectile dysfunction) in the presence of elevated LDH  $\geq 2 \times$  ULN, after prior LDH reduction to  $< 1.5 \times$  ULN on therapy.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline through Day 183

End point values	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	125	121		
Units: Percentage Of Participants				
number (confidence interval 95%)	4.0 (0.56 to 7.44)	10.7 (5.23 to 16.26)		

### Statistical analyses

Statistical analysis title	Analysis of BTH
----------------------------	-----------------

Statistical analysis description:

The difference of percentages was calculated using stratified Newcombe CI method. The stratification factors were: observed stratification groups of pRBC units transfused in the 1 year prior to first dose of study drug and screening LDH levels.

Comparison groups	Ravulizumab: Primary Evaluation v Eculizumab: Primary Evaluation
-------------------	--

Number of subjects included in analysis	246
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[3]</sup>
Parameter estimate	Treatment Difference
Point estimate	-6.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.21
upper limit	0.18

Notes:

[3] - Noninferiority margin was based on the upper bound of the 95% CI. Noninferiority margin was 20%.

### Secondary: Percentage Of Participants With Stabilized Hemoglobin Levels

End point title	Percentage Of Participants With Stabilized Hemoglobin Levels
End point description:	
Stabilized hemoglobin was defined as avoidance of a $\geq 2$ g/dL decrease in hemoglobin level from baseline in the absence of transfusion through Day 183.	
End point type	Secondary
End point timeframe:	
Baseline through Day 183	

End point values	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	125	121		
Units: Percentage of Participants				
number (confidence interval 95%)	68.0 (59.82 to 76.18)	64.5 (55.93 to 72.99)		

### Statistical analyses

<b>Statistical analysis title</b>	Analysis of Stabilized Hemoglobin Levels
Statistical analysis description:	
The difference of percentages was calculated using stratified Newcombe CI method. The stratification factors were: observed stratification groups of pRBC units transfused in the 1 year prior to first dose of study drug and screening LDH levels.	
Comparison groups	Ravulizumab: Primary Evaluation v Eculizumab: Primary Evaluation
Number of subjects included in analysis	246
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[4]</sup>
Parameter estimate	Treatment Difference
Point estimate	2.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	14.64

Notes:

[4] - Noninferiority margin was based on the lower bound of the 95% CI. Noninferiority margin was -20%.

### Secondary: Percent Change From Baseline In LDH Levels

End point title	Percent Change From Baseline In LDH Levels
-----------------	--

End point description:

Baseline is defined as the average of all available assessments of LDH levels prior to first study drug dose. Estimates are based on mixed model for repeated measures (MMRM) that includes treatment group, history of transfusion (as a categorical variable based on the stratification factor levels) and baseline LDH level (as a continuous variable), study visit, and study visit by treatment group interaction. An unstructured covariance structure was used.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Day 183

End point values	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	125	121		
Units: Percent Change				
least squares mean (confidence interval 95%)	-76.84 (-79.96 to -73.73)	-76.02 (-79.20 to -72.83)		

### Statistical analyses

<b>Statistical analysis title</b>	Analysis of LDH
Comparison groups	Ravulizumab: Primary Evaluation v Eculizumab: Primary Evaluation
Number of subjects included in analysis	246
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[5]</sup>
Parameter estimate	Treatment Difference
Point estimate	-0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.21
upper limit	3.56

Notes:

[5] - Noninferiority margin was based on the upper bound of the 95% CI. Noninferiority margin was 20%.

## Secondary: Change From Baseline In Quality Of Life As Assessed By The Functional Assessment Of Chronic Illness Therapy-Fatigue

End point title	Change From Baseline In Quality Of Life As Assessed By The Functional Assessment Of Chronic Illness Therapy-Fatigue
-----------------	---

### End point description:

The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline is defined as the last non-missing value prior to first dose of study drug. Estimates are based on MMRM that includes treatment group, the observed stratification randomization indicators (history of transfusion and LDH) and baseline FACIT-Fatigue level, study visit, and study visit by treatment group interaction. An unstructured covariance structure was used.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline, Day 183

End point values	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	125	121		
Units: Units On A Scale				
least squares mean (confidence interval 95%)	7.07 (5.55 to 8.60)	6.40 (4.85 to 7.96)		

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of FACIT-Fatigue
Comparison groups	Ravulizumab: Primary Evaluation v Eculizumab: Primary Evaluation
Number of subjects included in analysis	246
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[6]</sup>
Parameter estimate	Treatment Difference
Point estimate	0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.21
upper limit	2.55

### Notes:

[6] - Noninferiority margin was based on the lower bound of the 95% CI. Noninferiority margin was -5%.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to Day 2045

Adverse event reporting additional description:

TEAEs reported below include those that occurred during or after first infusion of study treatment up to Day 2045 (end of study). All cause mortality and number of participants who discontinued due to AEs in the AE section reports number of participants during study and number of participants who died after they were discontinued from study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Ravulizumab: Primary Evaluation
-----------------------	---------------------------------

Reporting group description:

Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 mg on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.

Reporting group title	Eculizumab: Primary Evaluation
-----------------------	--------------------------------

Reporting group description:

Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.

Reporting group title	Ravulizumab/Ravulizumab: Extension Period
-----------------------	---

Reporting group description:

After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 5 years.

Reporting group title	Eculizumab/Ravulizumab: Extension Period
-----------------------	--

Reporting group description:

After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants received weight-based doses of ravulizumab for up to 5 years.

Reporting group title	Ravulizumab-Adults
-----------------------	--------------------

Reporting group description:

Participants in this group rolled over from other ongoing studies of ravulizumab intravenous in participants with PNH into the extension period of this study and received weight-based doses of ravulizumab for up to 5 years.

Reporting group title	Ravulizumab-Pediatrics
-----------------------	------------------------

Reporting group description:

Participants in this group rolled over from other ongoing studies of ravulizumab intravenous in participants with PNH into the extension period of this study and received weight-based doses of ravulizumab for up to 5 years.

<b>Serious adverse events</b>	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation	Ravulizumab/Ravulizumab: Extension Period
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 125 (8.80%)	9 / 121 (7.44%)	52 / 125 (41.60%)
number of deaths (all causes)	0	0	4
number of deaths resulting from adverse events	0	0	4

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung adenocarcinoma			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Adenocarcinoma gastric			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinonasal papilloma			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Peripheral artery thrombosis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 125 (0.80%)	2 / 121 (1.65%)	4 / 125 (3.20%)
occurrences causally related to treatment / all	1 / 1	0 / 2	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Allergy to vaccine			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Pulmonary embolism			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			

subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Investigations</b>			
Blood bilirubin increased			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoglobin decreased			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Skin laceration			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Road traffic accident subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Branchial cyst subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial ischaemia subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Nervous system disorders</b>			
Cerebral venous thrombosis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Headache</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Intracranial pressure increased</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Migraine</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cerebrovascular accident</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Aplastic anaemia</b>			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	5 / 125 (4.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Anaemia</b>			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	7 / 125 (5.60%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Thrombocytopenia</b>			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Neutropenia			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemolysis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	4 / 125 (3.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemolytic anaemia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breakthrough haemolysis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Neutropenic colitis			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			

subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal discomfort			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric varices			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			

subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholecystitis acute</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Jaundice</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholecystitis chronic</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Skin ulcer</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
<b>Renal colic</b>			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Paroxysmal nocturnal haemoglobinuria</b>			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Acute kidney injury</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hydronephrosis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteonecrosis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Leptospirosis			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic infection			
subjects affected / exposed	1 / 125 (0.80%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 125 (0.00%)	1 / 121 (0.83%)	5 / 125 (4.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	6 / 125 (4.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	3 / 125 (2.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			

subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	2 / 125 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus infection			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chikungunya virus infection			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			

subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial infection			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Meningococcal sepsis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Upper respiratory tract infection			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			

subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Fungal endocarditis</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endophthalmitis</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endometritis</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nasopharyngitis</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary sepsis</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sinusitis</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyelonephritis acute</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Dehydration			

subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haemochromatosis</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyperglycaemia</b>			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Ecuzumab/Ravulizumab: Extension Period	Ravulizumab-Adults	Ravulizumab-Pediatrics
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	43 / 119 (36.13%)	2 / 24 (8.33%)	0 / 2 (0.00%)
number of deaths (all causes)	4	0	0
number of deaths resulting from adverse events	4	0	0
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>Lung adenocarcinoma</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Uterine leiomyoma</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Acute myeloid leukaemia</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Adenocarcinoma gastric</b>			

subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinonasal papilloma			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	2 / 119 (1.68%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery thrombosis			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	3 / 119 (2.52%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Immune system disorders			
Allergy to vaccine			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal septum deviation			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoglobin decreased			

subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Skin laceration			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	2 / 119 (1.68%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Congenital, familial and genetic disorders</b>			
Branchial cyst			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
Myocardial ischaemia			

subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral venous thrombosis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial pressure increased			

subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Migraine</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cerebrovascular accident</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Aplastic anaemia</b>			
subjects affected / exposed	1 / 119 (0.84%)	1 / 24 (4.17%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Anaemia</b>			
subjects affected / exposed	2 / 119 (1.68%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Thrombocytopenia</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutropenia</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile neutropenia</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haemolysis</b>			

subjects affected / exposed	2 / 119 (1.68%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haemolytic anaemia</b>			
subjects affected / exposed	3 / 119 (2.52%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Breakthrough haemolysis</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancytopenia</b>			
subjects affected / exposed	3 / 119 (2.52%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Neutropenic colitis</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ileus</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Abdominal hernia</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Abdominal discomfort</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Obstructive pancreatitis</b>			

subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Oesophageal varices haemorrhage</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancreatitis acute</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastric varices</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
<b>Cholecystitis</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholelithiasis</b>			
subjects affected / exposed	0 / 119 (0.00%)	1 / 24 (4.17%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholangitis</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholecystitis acute</b>			
subjects affected / exposed	4 / 119 (3.36%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Jaundice</b>			

subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cholecystitis chronic</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Skin ulcer</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
<b>Renal colic</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Paroxysmal nocturnal haemoglobinuria</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Acute kidney injury</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hydronephrosis</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nephrolithiasis</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Musculoskeletal and connective tissue disorders</b>			
Osteonecrosis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Abscess limb			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leptospirosis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Systemic infection			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	6 / 119 (5.04%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	2 / 8	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	3 / 119 (2.52%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	2 / 119 (1.68%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			

subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus infection			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chikungunya virus infection			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial infection			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningococcal sepsis			

subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 119 (1.68%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungal endocarditis			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endophthalmitis			

subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endometritis</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nasopharyngitis</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary sepsis</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
<b>Sinusitis</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyelonephritis acute</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>Dehydration</b>			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haemochromatosis</b>			
subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyperglycaemia</b>			

subjects affected / exposed	1 / 119 (0.84%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Ravulizumab: Primary Evaluation	Eculizumab: Primary Evaluation	Ravulizumab/Ravulizumab: Extension Period
Total subjects affected by non-serious adverse events			
subjects affected / exposed	87 / 125 (69.60%)	86 / 121 (71.07%)	102 / 125 (81.60%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	7 / 125 (5.60%)
occurrences (all)	0	0	10
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	6 / 125 (4.80%)	11 / 121 (9.09%)	22 / 125 (17.60%)
occurrences (all)	6	14	27
Chest pain			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	8 / 125 (6.40%)
occurrences (all)	0	0	10
Fatigue			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	5 / 125 (4.00%)
occurrences (all)	0	0	5
Asthenia			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	0 / 125 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	8 / 125 (6.40%)	6 / 121 (4.96%)	0 / 125 (0.00%)
occurrences (all)	10	6	0
Cough			
subjects affected / exposed	4 / 125 (3.20%)	8 / 121 (6.61%)	14 / 125 (11.20%)
occurrences (all)	4	11	21
Epistaxis			

subjects affected / exposed occurrences (all)	0 / 125 (0.00%) 0	0 / 121 (0.00%) 0	4 / 125 (3.20%) 4
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	2 / 125 (1.60%) 2	6 / 121 (4.96%) 7	11 / 125 (8.80%) 14
Investigations C-reactive protein increased subjects affected / exposed occurrences (all)  Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 125 (0.00%) 0  0 / 125 (0.00%) 0	0 / 121 (0.00%) 0  0 / 121 (0.00%) 0	2 / 125 (1.60%) 4  9 / 125 (7.20%) 12
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	7 / 125 (5.60%) 10	2 / 121 (1.65%) 2	0 / 125 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)  Dizziness subjects affected / exposed occurrences (all)	45 / 125 (36.00%) 70  9 / 125 (7.20%) 9	40 / 121 (33.06%) 71  7 / 121 (5.79%) 10	16 / 125 (12.80%) 30  4 / 125 (3.20%) 10
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)  Neutropenia subjects affected / exposed occurrences (all)  Thrombocytopenia subjects affected / exposed occurrences (all)  Leukopenia subjects affected / exposed occurrences (all)	3 / 125 (2.40%) 3  0 / 125 (0.00%) 0  0 / 125 (0.00%) 0  0 / 125 (0.00%) 0	6 / 121 (4.96%) 9  0 / 121 (0.00%) 0  0 / 121 (0.00%) 0  0 / 121 (0.00%) 0	4 / 125 (3.20%) 5  9 / 125 (7.20%) 12  8 / 125 (6.40%) 15  7 / 125 (5.60%) 12

Gastrointestinal disorders			
Nausea			
subjects affected / exposed	11 / 125 (8.80%)	10 / 121 (8.26%)	8 / 125 (6.40%)
occurrences (all)	14	14	9
Diarrhoea			
subjects affected / exposed	10 / 125 (8.00%)	5 / 121 (4.13%)	14 / 125 (11.20%)
occurrences (all)	12	7	16
Abdominal pain			
subjects affected / exposed	7 / 125 (5.60%)	7 / 121 (5.79%)	10 / 125 (8.00%)
occurrences (all)	7	7	13
Dyspepsia			
subjects affected / exposed	5 / 125 (4.00%)	6 / 121 (4.96%)	8 / 125 (6.40%)
occurrences (all)	7	7	12
Vomiting			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	7 / 125 (5.60%)
occurrences (all)	0	0	7
Abdominal pain upper			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	10 / 125 (8.00%)
occurrences (all)	0	0	14
Constipation			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	10 / 125 (8.00%)
occurrences (all)	0	0	11
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	4 / 125 (3.20%)	6 / 121 (4.96%)	0 / 125 (0.00%)
occurrences (all)	4	6	0
Rash			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	1 / 125 (0.80%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	11 / 125 (8.80%)	11 / 121 (9.09%)	17 / 125 (13.60%)
occurrences (all)	17	12	19
Pain in extremity			
subjects affected / exposed	9 / 125 (7.20%)	6 / 121 (4.96%)	0 / 125 (0.00%)
occurrences (all)	10	7	0

Back pain			
subjects affected / exposed	8 / 125 (6.40%)	6 / 121 (4.96%)	12 / 125 (9.60%)
occurrences (all)	9	6	13
Myalgia			
subjects affected / exposed	9 / 125 (7.20%)	9 / 121 (7.44%)	4 / 125 (3.20%)
occurrences (all)	14	12	9
<b>Infections and infestations</b>			
Viral upper respiratory tract infection			
subjects affected / exposed	9 / 125 (7.20%)	8 / 121 (6.61%)	0 / 125 (0.00%)
occurrences (all)	10	10	0
Upper respiratory tract infection			
subjects affected / exposed	13 / 125 (10.40%)	7 / 121 (5.79%)	30 / 125 (24.00%)
occurrences (all)	15	7	68
Nasopharyngitis			
subjects affected / exposed	11 / 125 (8.80%)	20 / 121 (16.53%)	14 / 125 (11.20%)
occurrences (all)	14	22	28
Oral herpes			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	5 / 125 (4.00%)
occurrences (all)	0	0	6
Gastroenteritis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	3 / 125 (2.40%)
occurrences (all)	0	0	5
Cystitis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	8 / 125 (6.40%)
occurrences (all)	0	0	8
Influenza			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	9 / 125 (7.20%)
occurrences (all)	0	0	10
COVID-19			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	19 / 125 (15.20%)
occurrences (all)	0	0	22
Bronchitis			
subjects affected / exposed	0 / 125 (0.00%)	0 / 121 (0.00%)	3 / 125 (2.40%)
occurrences (all)	0	0	3
Urinary tract infection			

subjects affected / exposed occurrences (all)	0 / 125 (0.00%) 0	0 / 121 (0.00%) 0	8 / 125 (6.40%) 10
Metabolism and nutrition disorders Hypokalaemia subjects affected / exposed occurrences (all)	0 / 125 (0.00%) 0	0 / 121 (0.00%) 0	12 / 125 (9.60%) 18

<b>Non-serious adverse events</b>	Eculizumab/Ravulizumab: Extension Period	Ravulizumab-Adults	Ravulizumab-Pediatrics
Total subjects affected by non-serious adverse events subjects affected / exposed	100 / 119 (84.03%)	13 / 24 (54.17%)	0 / 2 (0.00%)
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	4 / 119 (3.36%) 4	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	18 / 119 (15.13%) 22	2 / 24 (8.33%) 2	0 / 2 (0.00%) 0
Chest pain subjects affected / exposed occurrences (all)	3 / 119 (2.52%) 3	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	10 / 119 (8.40%) 11	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Asthenia subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	4 / 24 (16.67%) 4	0 / 2 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	18 / 119 (15.13%) 21	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Epistaxis			

subjects affected / exposed occurrences (all)	7 / 119 (5.88%) 9	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	6 / 119 (5.04%) 6	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Investigations C-reactive protein increased subjects affected / exposed occurrences (all)  Alanine aminotransferase increased subjects affected / exposed occurrences (all)	6 / 119 (5.04%) 7  8 / 119 (6.72%) 18	0 / 24 (0.00%) 0  0 / 24 (0.00%) 0	0 / 2 (0.00%) 0  0 / 2 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 119 (0.00%) 0	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)  Dizziness subjects affected / exposed occurrences (all)	20 / 119 (16.81%) 26  9 / 119 (7.56%) 9	2 / 24 (8.33%) 3  0 / 24 (0.00%) 0	0 / 2 (0.00%) 0  0 / 2 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)  Neutropenia subjects affected / exposed occurrences (all)  Thrombocytopenia subjects affected / exposed occurrences (all)  Leukopenia subjects affected / exposed occurrences (all)	10 / 119 (8.40%) 17  3 / 119 (2.52%) 3  4 / 119 (3.36%) 8  3 / 119 (2.52%) 3	0 / 24 (0.00%) 0  0 / 24 (0.00%) 0  0 / 24 (0.00%) 0  0 / 24 (0.00%) 0	0 / 2 (0.00%) 0  0 / 2 (0.00%) 0  0 / 2 (0.00%) 0  0 / 2 (0.00%) 0

Gastrointestinal disorders			
Nausea			
subjects affected / exposed	11 / 119 (9.24%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	17	0	0
Diarrhoea			
subjects affected / exposed	13 / 119 (10.92%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	19	0	0
Abdominal pain			
subjects affected / exposed	12 / 119 (10.08%)	2 / 24 (8.33%)	0 / 2 (0.00%)
occurrences (all)	17	3	0
Dyspepsia			
subjects affected / exposed	10 / 119 (8.40%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	20	0	0
Vomiting			
subjects affected / exposed	4 / 119 (3.36%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	5	0	0
Abdominal pain upper			
subjects affected / exposed	5 / 119 (4.20%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	5	0	0
Constipation			
subjects affected / exposed	5 / 119 (4.20%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	5	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	7 / 119 (5.88%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	7	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	12 / 119 (10.08%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	14	0	0
Pain in extremity			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0

Back pain			
subjects affected / exposed	11 / 119 (9.24%)	2 / 24 (8.33%)	0 / 2 (0.00%)
occurrences (all)	12	2	0
Myalgia			
subjects affected / exposed	7 / 119 (5.88%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	7	0	0
<b>Infections and infestations</b>			
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 119 (0.00%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	25 / 119 (21.01%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	36	0	0
Nasopharyngitis			
subjects affected / exposed	26 / 119 (21.85%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	47	0	0
Oral herpes			
subjects affected / exposed	6 / 119 (5.04%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	8	0	0
Gastroenteritis			
subjects affected / exposed	9 / 119 (7.56%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	9	0	0
Cystitis			
subjects affected / exposed	4 / 119 (3.36%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	8	0	0
Influenza			
subjects affected / exposed	11 / 119 (9.24%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	12	0	0
COVID-19			
subjects affected / exposed	16 / 119 (13.45%)	9 / 24 (37.50%)	0 / 2 (0.00%)
occurrences (all)	17	10	0
Bronchitis			
subjects affected / exposed	7 / 119 (5.88%)	0 / 24 (0.00%)	0 / 2 (0.00%)
occurrences (all)	8	0	0
Urinary tract infection			

subjects affected / exposed occurrences (all)	3 / 119 (2.52%) 4	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0
Metabolism and nutrition disorders Hypokalaemia subjects affected / exposed occurrences (all)	4 / 119 (3.36%) 4	0 / 24 (0.00%) 0	0 / 2 (0.00%) 0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 September 2016	<ul style="list-style-type: none"><li>• Modified the weight-based dosing for ravulizumab. The initial dosing regimen was designed to achieve complete inhibition of terminal complement activity over the entire dosing interval in all participants. After discussion with the United States Food and Drug Administration, it was determined that these slightly lower dosing levels also met the initially established trough exposure levels to ensure complete inhibition of complement component 5 activity in all participants. Changes were as follows: – For participants weighing <math>\geq 40</math> to <math>&lt; 60</math> kilograms (kg): Loading dose changed from 2700 mg to 2400 mg and maintenance dose changed from 3300 mg to 3000 mg – For participants weighing <math>\geq 60</math> to <math>&lt; 100</math> kg: Loading dose changed from 3000 mg to 2700 mg and maintenance dose changed from 3600 mg to 3300 mg – For participants weighing <math>\geq 100</math> kg: Loading dose unchanged and maintenance dose changed from 3900 mg to 3600 mg • The Dosing Reference Chart for ravulizumab Dose Preparation also was modified accordingly.</li></ul>
25 January 2017	<ul style="list-style-type: none"><li>• Clarified that all safety data, including those in the Extension Period, would be reported.</li><li>• Text added to address recommendations from regulatory authorities to incorporate a benefit-risk assessment summary in the study protocol. This included addition of a reference.</li><li>• An additional secondary objective was added to gain an understanding of the benefit-risk of switching participants from eculizumab to ravulizumab.</li><li>• Text was added as follows to minimize participant discomfort: To minimize needle sticks to the participant, the predose sample may be drawn through the venous access created for the dose infusion, prior to administration of the dose.</li><li>• A study visit on Day 225 was added globally to the Extension Period for participants who received eculizumab during the Primary Evaluation Period, to allow for assessment 4 weeks after their first maintenance dose of ravulizumab.</li><li>• Text added to ensure independent review of meningococcal infection cases.</li></ul>
23 October 2017	<ul style="list-style-type: none"><li>• Revised the statistical analysis description regarding control of Type I error when testing the primary and secondary end points for noninferiority and superiority.</li><li>• Clarified that the last recorded study visit body weight should be used for determination of weight-based dose, and if study drug is prepared the night before a visit, the weight from the most recent study visit should be used.</li><li>• Indicated the maximum permitted duration of an eculizumab infusion.</li><li>• In order to reduce the incidence of ex vivo hemolyzed blood samples, it was specified that draws should not be made via a heparinized tube.</li><li>• To reduce the participant data collection burden, removed the exploratory end points of Patient-Reported PNH Symptoms and Healthcare Resource Utilization, their description, and the questionnaires.</li><li>• Clarified that transfusions administered in the inpatient or outpatient setting should not be captured as adverse events or serious adverse events unless identified as such by the Investigator.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

## Online references

<http://www.ncbi.nlm.nih.gov/pubmed/30510080>